NEW
YORK, May 12, 2023 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Fulcrum Therapeutics, Inc.
(NASDAQ: FULC).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/fulcrum-class-action-loss-submission-form/?id=39283&from=4
The lawsuit seeks to recover losses for shareholders who
purchased Fulcrum between March 3,
2022 and March 8, 2023.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
June 27, 2023 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, Fulcrum Therapeutics, Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (i) the preclinical data submitted in support of
FTX-6058 (an investigational oral fetal hemoglobin inducer for the
treatment of sickle cell disease and other hemoglobinopathies)
showed safety concerns regarding potential hematological
malignancies; (ii) the foregoing safety concerns increased the
likelihood that the FDA would place a clinical hold on preclinical
studies of FTX-6058; (iii) accordingly, the Company had overstated
FTX-6058's clinical and/or commercial prospects; and (iv) as a
result, the Company's public statements were materially false and
misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/fulc-shareholder-alert-jakubowitz-law-reminds-fulcrum-shareholders-of-a-lead-plaintiff-deadline-of-june-27-2023-301822948.html
SOURCE Jakubowitz Law